Allen Feng

Allen is the Founder and Chief Scientific Officer of HebeCell Corp. Prior to HebeCell, Allen was the Director of Cell Biology of Semma Therapeutics (Acquired by Vertex), R&D Head of Stem Cell Bioprocessing Group at EMD Millipore (Merck, KGaA), Director and Senior Scientist at Advanced Cell Technology (Acquired by Astellas), and Senior Scientist at Stemgent, Inc (Now ReproCell). Allen is an inventor of several key patents of hematopoietic lineage-specific differentiation from human pluripotent stem cells (hPSCs), such as the generation of HLA-negative platelets, and a scalable 3D manufacture platform of NK from hPSCs.